Literature DB >> 10463574

Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.

R Koesters1, R Ridder, A Kopp-Schneider, D Betts, V Adams, F Niggli, J Briner, M von Knebel Doeberitz.   

Abstract

Activation of beta-catenin-mediated transcription is the nuclear end point of organ-specific Wnt signaling. In the developing kidney, Wnt-4, a secreted glycoprotein, acts as an autoinducer of the mesenchymal to epithelial transition that underlies normal nephron development. Dysregulation of this epithelial transformation process may lead to Wilms' tumors (WTs). In this study, we investigated the potential role of the beta-catenin proto-oncogene, a candidate downstream target molecule of Wnt-4 signaling, in the development of WTs. In 6 of 40 tumors (15%), mutation analysis revealed heterozygous missense mutations or small deletions that result in the loss of important regulatory phosphorylation sites within the beta-catenin protein. These findings indicate that activating beta-catenin mutations may play a significant role in the development of WTs and establish a direct link between Wilms' tumorigenesis and the Wnt signal transduction pathway governing normal kidney development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10463574

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  78 in total

1.  Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children.

Authors:  Masayuki Haruta; Yasuhito Arai; Naoki Watanabe; Yuiko Fujiwara; Shohei Honda; Junjiro Ohshima; Fumio Kasai; Hisaya Nakadate; Hiroshi Horie; Hajime Okita; Jun-Ichi Hata; Masahiro Fukuzawa; Yasuhiko Kaneko
Journal:  Cancer Sci       Date:  2012-04-19       Impact factor: 6.716

2.  Tankyrase is necessary for canonical Wnt signaling during kidney development.

Authors:  Courtney M Karner; Calli E Merkel; Michael Dodge; Zhiqiang Ma; Jianming Lu; Chuo Chen; Lawrence Lum; Thomas J Carroll
Journal:  Dev Dyn       Date:  2010-07       Impact factor: 3.780

3.  Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.

Authors:  Richard D Williams; Reem Al-Saadi; Tasnim Chagtai; Sergey Popov; Boo Messahel; Neil Sebire; Manfred Gessler; Jenny Wegert; Norbert Graf; Ivo Leuschner; Mike Hubank; Chris Jones; Gordan Vujanic; Kathy Pritchard-Jones
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

Review 4.  Exploring the functions of RNA interference pathway proteins: some functions are more RISCy than others?

Authors:  Katarzyna Jaronczyk; Jon B Carmichael; Tom C Hobman
Journal:  Biochem J       Date:  2005-05-01       Impact factor: 3.857

Review 5.  Wilms' tumour: a complex enigma to decipher.

Authors:  María José Robles-Frías; Michele Biscuola; María Angeles Castilla; María Angeles López-García; Felicia Sánchez-Gallego; José Palacios
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

6.  CITED1 expression in Wilms' tumor and embryonic kidney.

Authors:  Harold N Lovvorn; Jenifer Westrup; Shaun Opperman; Scott Boyle; Genbin Shi; James Anderson; Elizabeth J Perlman; Alan O Perantoni; Marcia Wills; Mark de Caestecker
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

7.  CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.

Authors:  Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

8.  Wilms tumor arising in a child with X-linked nephrogenic diabetes insipidus.

Authors:  Reyhan El-Kares; Pierre-Alain Hueber; Miriam Blumenkrantz; Diana Iglesias; Kim Ma; Nada Jabado; Daniel G Bichet; Paul Goodyer
Journal:  Pediatr Nephrol       Date:  2009-03-18       Impact factor: 3.714

9.  Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.

Authors:  Andy J Chien; Erin C Moore; Anke S Lonsdorf; Rima M Kulikauskas; Bonnie Gould Rothberg; Aaron J Berger; Michael B Major; Sam T Hwang; David L Rimm; Randall T Moon
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-14       Impact factor: 11.205

10.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.